Ultragenyx SVP granted RSUs and stock options

Ultragenyx Pharmaceutical Inc. reported that SVP and Chief Accounting Officer Theodore Alan Huizenga received an equity compensation grant.

Rhea-AI Filing Summary

Ultragenyx Pharmaceutical Inc. reported that SVP and Chief Accounting Officer Theodore Alan Huizenga received an equity compensation grant. He was awarded 20,241 shares of common stock in the form of restricted stock units, increasing his direct holdings to 68,911 shares. These RSUs vest in four equal annual installments on each anniversary of the grant date, becoming fully vested after four years.

He also received a stock option for 7,348 shares of common stock with an exercise price of $24.61 per share, expiring on April 22, 2036. One quarter of the option vests on the first anniversary of the grant date, with the remainder vesting in equal monthly installments thereafter.

Insider Trade Summary

Grant/Award: 27,589 shares

Grant/Award 2 txns

Insider Huizenga Theodore Alan

Role SVP, Chief Accounting Officer

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	7,348	$0.00	$0.00
Grant/Award	Common Stock	20,241	$0.00	$0.00

Holdings After Transaction: Stock Option (Right to Buy) — 7,348 contracts (Direct); Common Stock — 68,911 shares (Direct)

Footnotes (3)

1. F1. Award of Restricted Stock Units ("RSUs") under the Company's 2023 Incentive Plan. The RSUs shall vest with respect to 1/4th of the underlying shares on each anniversary of the grant date, such that the RSUs are fully vested on the fourth anniversary of the grant date
2. F2. Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions.
3. F3. On the first anniversary of the grant date of the option (the "Option Anniversary Date"), 1/4th of the shares initially subject to the option shall vest; thereafter, 1/48th of the shares initially subject to the option shall vest on each month as measured from the Option Anniversary Date.

Key Figures

RSU grant: 20,241 shares Shares held after grant: 68,911 shares Stock option size: 7,348 shares +4 more

7 metrics

RSU grant 20,241 shares Restricted Stock Units granted April 22, 2026

Shares held after grant 68,911 shares Common stock directly held after RSU award

Stock option size 7,348 shares Option covering common stock granted April 22, 2026

Option exercise price $24.61 per share Stock Option (Right to Buy) exercise price

Option expiration April 22, 2036 Expiration date of granted stock option

RSU vesting schedule 25% annually over 4 years Vests on each anniversary of grant date

Option vesting schedule 25% at 1 year, then monthly 1/4 at first anniversary, then 1/48 monthly

Key Terms

Restricted Stock Units ("RSUs"), 2023 Incentive Plan, vesting conditions, Stock Option (Right to Buy), +1 more

5 terms

Restricted Stock Units ("RSUs") financial

"Award of Restricted Stock Units ("RSUs") under the Company's 2023 Incentive Plan."

Restricted stock units (RSUs) are a company promise to give an employee shares of stock (or cash equivalent) in the future, but only after certain conditions—usually staying with the company for a set time or hitting performance goals—are met. Investors watch RSUs because when they vest they increase the number of shares outstanding and can lead insiders to sell shares, affecting share price, company dilution and the true cost of employee pay.

2023 Incentive Plan financial

"Award of Restricted Stock Units ("RSUs") under the Company's 2023 Incentive Plan."

vesting conditions financial

"Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions."

Vesting conditions are the rules that determine when someone earning company stock or stock options actually gains the right to keep or sell them, typically based on staying with the company for a set time or meeting performance targets. Think of it like keys that unlock gradually — some unlock by calendar date, others only after agreed milestones. Investors care because vesting shapes management incentives, the timing of share sales, and the number of shares that can enter the market, which can affect a company's valuation and ownership mix.

Stock Option (Right to Buy) financial

"Stock Option (Right to Buy)"

exercise price financial

"conversion_or_exercise_price": "24.6100""

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Ultragenyx (RARE) report for Theodore Alan Huizenga?

Ultragenyx reported that SVP and Chief Accounting Officer Theodore Alan Huizenga received equity compensation. He was granted 20,241 restricted stock units and a stock option for 7,348 shares, both awarded on April 22, 2026, as part of his compensation package.

How many Ultragenyx (RARE) shares does Theodore Huizenga hold after this Form 4?

After the grant, Theodore Huizenga directly holds 68,911 shares of Ultragenyx common stock. This total includes previously reported shares underlying restricted stock units that remain subject to vesting conditions, according to the Form 4 and its accompanying footnote disclosure.

What are the terms of Theodore Huizenga’s restricted stock units at Ultragenyx (RARE)?

Huizenga received 20,241 restricted stock units under Ultragenyx’s 2023 Incentive Plan. One quarter of the underlying shares vest on each anniversary of the grant date, so the award becomes fully vested on the fourth anniversary, assuming continued service during the vesting period.

What are the key details of the stock option granted to Theodore Huizenga at Ultragenyx (RARE)?

He received a stock option covering 7,348 Ultragenyx shares at a $24.61 exercise price, expiring April 22, 2036. One quarter vests on the first anniversary of the grant date, and the remaining shares vest in equal monthly installments measured from that anniversary date.

Is Theodore Huizenga’s Ultragenyx (RARE) Form 4 a market purchase or a compensation grant?

The Form 4 reflects equity compensation grants, not open-market trades. It reports an award of restricted stock units and a stock option grant, both with a transaction code “A,” indicating grants or awards provided by the company under its incentive compensation arrangements.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 04/24/2026 - 04:39 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Huizenga Theodore Alan

(Last) (First) (Middle)

C/O ULTRAGENYX PHARMACEUTICAL INC.

60 LEVERONI COURT

(Street)

NOVATO CALIFORNIA 94949

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Ultragenyx Pharmaceutical Inc. [ RARE ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	SVP, Chief Accounting Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
04/22/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	04/22/2026		A		20,241(1)	A	$0	68,911(2)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$24.61	04/22/2026		A		7,348		(3)	04/22/2036	Common Stock	7,348	$0	7,348	D

Explanation of Responses:

1. Award of Restricted Stock Units ("RSUs") under the Company's 2023 Incentive Plan. The RSUs shall vest with respect to 1/4th of the underlying shares on each anniversary of the grant date, such that the RSUs are fully vested on the fourth anniversary of the grant date

2. Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions.

3. On the first anniversary of the grant date of the option (the "Option Anniversary Date"), 1/4th of the shares initially subject to the option shall vest; thereafter, 1/48th of the shares initially subject to the option shall vest on each month as measured from the Option Anniversary Date.

	/s/ Karah Parschauer, attorney-in-fact	04/24/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)